Featured

Wegovy for Arthritis: Weight Loss Drug May Also Reduce Joint Inflammation, Says Study

Semaglutide, the active ingredient in the popular weight-loss medication Wegovy, is showing promising results not just for shedding pounds but also for easing the pain and inflammation associated with knee osteoarthritis. A major clinical trial suggests the drug could become a valuable option for people struggling with obesity-related joint problems.

The STEP 9 Trial: Key Findings

The evidence comes from the STEP 9 trial, a phase 3, double-blind, randomized, placebo-controlled study published in the New England Journal of Medicine in 2024. The trial involved 407 adults across 11 countries who had obesity (average BMI around 40.3) and moderate to severe knee osteoarthritis with significant pain.

Participants received either once-weekly injections of semaglutide (titrated up to the full 2.4 mg Wegovy dose) or a placebo, alongside counseling on a reduced-calorie diet and increased physical activity, for 68 weeks.

Results were notable:

  • Weight Loss: Participants on semaglutide lost an average of 13.7% of their body weight, compared to just 3.2% in the placebo group.
  • Pain Reduction: Knee pain scores (measured by the WOMAC index) dropped by 41.7 points with semaglutide versus 27.5 points with placebo — a clinically meaningful improvement.
  • Physical Function: Patients reported better mobility and daily function, with larger gains in physical-function scores.

The pain relief observed was comparable to some traditional pain medications, largely attributed to the substantial reduction in body weight, which decreases mechanical stress on the knees.

How It Works: Weight Loss Plus Potential Anti-Inflammatory Effects

The primary benefit appears to stem from weight loss, which relieves pressure on weight-bearing joints. However, researchers note that GLP-1 receptor agonists like semaglutide may offer additional advantages. These drugs can lower systemic inflammation markers such as C-reactive protein (CRP) and might directly influence joint tissue metabolism or provide cartilage protection, according to emerging preclinical and clinical data.

Observational studies have also linked semaglutide use in obese individuals to a reduced risk of developing osteoarthritis in the first place.

Limitations and Considerations

While encouraging, the findings have some caveats. The study focused specifically on knee osteoarthritis in people with obesity and was funded by Novo Nordisk, the manufacturer of Wegovy. It does not yet prove benefits for other forms of arthritis, such as rheumatoid arthritis, or for patients who are not obese.

Common side effects, primarily gastrointestinal issues like nausea, led to higher discontinuation rates in the semaglutide group. As with any medication, cost, long-term accessibility, and individual suitability remain important factors.

Experts emphasize that Wegovy should not replace standard osteoarthritis treatments but could serve as a helpful addition for eligible patients when weight management is a key concern.

For individuals with obesity and painful knee arthritis, Wegovy offers meaningful improvements in pain and function beyond what diet and exercise alone typically achieve. Ongoing research continues to explore its broader applications and mechanisms. Patients interested in this option should consult their doctor to discuss potential benefits, risks, and whether it fits their overall treatment plan.

Click to rate this post!
[Total: 0 Average: 0]

About The Author

Leave a Reply

Verified by MonsterInsights